Journal: Bioengineering & Translational Medicine

Article Title: Micelle encapsulation zinc‐doped copper oxide nanocomposites reverse Olaparib resistance in ovarian cancer by disrupting homologous recombination repair

doi: 10.1002/btm2.10507

Figure Lengend Snippet: Effects of MEnZn‐CuO NPs on the growth of ovarian cancer cell lines in vitro. (a) IC 50 curves of two Nano‐particles in the IOSE80 cell. (b) Dose‐response curves of MEnZn‐CuO NPs in a panel of seven cell lines treated with varying concentrations for 72 h. (c) Time inhibitory effect of the MEnZn‐CuO NPs on the ovarian cancer cell lines OVCAR8 and A2780. (d) The MEnZn‐CuO NPs inhibited the colony formation in ovarian cancer cells, significantly. (e) Ovarian cancer cell lines were cultured in 3D matrigel and MEnZn‐CuO NPs‐treated for 10–15 days. Error bars represent standard deviations (SD) from the mean. Representative images of cells are shown. Quantification of scored structures (intact, semi‐disintegrated and disintegrated) is shown. Scale bar, 50 μm. *p < 0.05; **p < 0.01; ***p < 0.001 (Student's t ‐test).

Article Snippet: SKOV3 and A2780 human ovarian cancer cell lines were purchased from iCell Bioscience Inc (China).

Techniques: In Vitro, Cell Culture

Journal: Bioengineering & Translational Medicine

Article Title: Micelle encapsulation zinc‐doped copper oxide nanocomposites reverse Olaparib resistance in ovarian cancer by disrupting homologous recombination repair

doi: 10.1002/btm2.10507

Figure Lengend Snippet: MEnZn‐CuO NPs significantly affected the migration, apoptosis and autophagy of OVCAR8 and A2780 ovarian cancer cell lines. (a) MEnZn‐CuO NPs inhibited the cell migration by scratch wound healing. (b) The apoptosis of OVCAR8 and A2780 ovarian cancer cell lines treated with MEnZn‐CuO NPs was identified by flow cytometry analysis. The autophagy of OVCAR8 (c) and A2780 (d) ovarian cancer cell lines treated with MEnZn‐CuO NPs was analysis by fluorescence microscope. Red puncta represent autolysosomes and yellow puncta represent autophagosomes *p < 0.05; **p < 0.01; ***p < 0.001 (Student's t test).

Article Snippet: SKOV3 and A2780 human ovarian cancer cell lines were purchased from iCell Bioscience Inc (China).

Techniques: Migration, Flow Cytometry, Fluorescence, Microscopy

Journal: Bioengineering & Translational Medicine

Article Title: Micelle encapsulation zinc‐doped copper oxide nanocomposites reverse Olaparib resistance in ovarian cancer by disrupting homologous recombination repair

doi: 10.1002/btm2.10507

Figure Lengend Snippet: MEnZn‐CuO NPs induced DNA damage and chromosome instability in ovarian cancer cell lines. (a) DNA damage in A2780 and OVCAR8 ovarian cancer cell lines after 48 h treatment with MEnZn‐CuO NPs was examined by comet assay. Scale bar, 100 μm. (b) The expression of γH2AX and RAD51 in A2780 and OVCAR8 ovarian cancer cell lines after 48 h treatment with MEnZn‐CuO NPs was detected by immunofluorescence staining. Scale bar, 20 μm. Cells containing more than five foci were scored as positive. (c) The mRNA level of HR gene BRCA1, BRCA1and ATM in A2780 and OVCAR8 ovarian cancer cell lines treated with MEnZn‐CuO NPs as indicated for 24 h was identified by quantitative transcription PCR analysis. (d) The chromosome aberrations in A2780 and OVCAR8 ovarian cancer cell lines after 48 h treatment with MEnZn‐CuO NPs was detected by metaphase chromosome spread assay. Scale bar, 10 μm. Mean ± S.D. for three independent experiments were shown. *p < 0.05; **p < 0.01; ***p < 0.001 (Student's t test).

Article Snippet: SKOV3 and A2780 human ovarian cancer cell lines were purchased from iCell Bioscience Inc (China).

Techniques: Single Cell Gel Electrophoresis, Expressing, Immunofluorescence, Staining

Journal: Bioengineering & Translational Medicine

Article Title: Micelle encapsulation zinc‐doped copper oxide nanocomposites reverse Olaparib resistance in ovarian cancer by disrupting homologous recombination repair

doi: 10.1002/btm2.10507

Figure Lengend Snippet: Effects of Olaparib and MEnZn‐CuO NPs monotherapy or in combination on the growth of ovarian cancer cell lines in vitro. (a) Dose‐response curves of Olaparib in a panel of six ovarian cancer cell lines treated with varying concentrations for 72 h. (b) The synergistic effect of Olaparib combined with MEnZn‐CuO NPs in A2780, OVCAR3, OVCAR8, and SNU119 ovarian cancer cells was detected by FA‐CI method. (c) Effect of Olaparib and MEnZn‐CuO NPs alone or in combination on colony formation in A2780, OVCAR3, OVCAR8, and SNU119 ovarian cancer cell lines. Representative images are shown. (d) Flow cytometry analysis of Annexin V and PI‐stained cells to assess the effect of Olaparib and MEnZn‐CuO NPs monotherapy or combination on apoptosis in A2780, OVCAR3, OVCAR8, and SNU119 ovarian cancer cell lines. Mean ± S.D. for three independent experiments were shown. *p < 0.05; **p < 0.01; ***p < 0.001 (Student's t test).

Article Snippet: SKOV3 and A2780 human ovarian cancer cell lines were purchased from iCell Bioscience Inc (China).

Techniques: In Vitro, Flow Cytometry, Staining

Journal: Bioengineering & Translational Medicine

Article Title: Micelle encapsulation zinc‐doped copper oxide nanocomposites reverse Olaparib resistance in ovarian cancer by disrupting homologous recombination repair

doi: 10.1002/btm2.10507

Figure Lengend Snippet: Olaparib in combination with MEnZn‐CuO NPs caused DNA damage and chromosomal instability in ovarian cancer cell lines. (a) DNA damage in A2780, OVCAR8 and OVCAR3 ovarian cancer cell lines was detected by comet assay after 48 h of drug treatment. Scale bar, 100 μm. (b) Expression of γH2AX and RAD51 in A2780, OVCAR8 and OVCAR3 ovarian cancer cell lines was detected by immunofluorescence assay 48 h after drug treatment. Scale bar, 20 μm (c) The mRNA levels of homologous recombinant genes BRCA1, BRCA1 and ATM in A2780, OVCAR8 and OVCAR3 ovarian cancer cell lines were detected by real‐time quantitative PCR assay 24 h after drug treatment. And the quality of relative expression of γH2AX. Mean ± S.D. for three independent experiments were shown. *p < 0.05; **p < 0.01; ***p < 0.001 (Student's t test).

Article Snippet: SKOV3 and A2780 human ovarian cancer cell lines were purchased from iCell Bioscience Inc (China).

Techniques: Single Cell Gel Electrophoresis, Expressing, Immunofluorescence, Recombinant, Real-time Polymerase Chain Reaction

Journal: Bioengineering & Translational Medicine

Article Title: Micelle encapsulation zinc‐doped copper oxide nanocomposites reverse Olaparib resistance in ovarian cancer by disrupting homologous recombination repair

doi: 10.1002/btm2.10507

Figure Lengend Snippet: Combined use of Olaparib and MEnZn‐CuO NPs showed synergistic effects in vivo. (a) Tumor growth curves of A2780 xenograft mice treated with Olaparib (50 mg/kg/day) and MEnZn‐CuO NPs (5 mg/kg/day) alone or in combination. Day 0 was the treatment start date. tumor size was measured once daily for 14 days. (b) Body weight change of mice per day during treatment. (c) Pictures of A2780 xenograft tumors isolated from mice in different treatment groups at the end of the experiment. (d) Representative images of HE staining of A2780 xenograft tumors using Olaparib and MEnZn‐CuO NPs alone or in combination for 14 days. Scale bar, 100 μm. (e) Representative images of immunohistochemical staining of A2780 xenograft tumors obtained at the end of treatment. Scale bar, 50 μm. Data are shown as the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 (one‐way ANOVA with Tukey's multiple comparison test).

Article Snippet: SKOV3 and A2780 human ovarian cancer cell lines were purchased from iCell Bioscience Inc (China).

Techniques: In Vivo, Isolation, Staining, Immunohistochemical staining, Comparison